Octreotide treatment of carcinoid syndrome: analysis of published dose‐titration data

Alimentary Pharmacology & Therapeutics

Volumn 9, Issue 4, 1995, Pages 387-394

  HARRIS, A G ^a   REDFERN, J S ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; OCTREOTIDE;

ARTICLE; CARCINOID SYNDROME; CLINICAL TRIAL; DATA BASE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG THERAPY; FLUSHING; HUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

CARCINOID TUMOR; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUSHING; FOLLOW-UP STUDIES; HUMAN; OCTREOTIDE; STATISTICS; SUPPORT, NON-U.S. GOV'T;

EID: 0029029785     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.1995.tb00396.x     Document Type: Review

References (83)

1. Therapy of the malignant carcinoid syndrome and metastatic islet cell carcinoma
2. Therapy of the malignant carcinoid syndrome
3. Treatment of the carcinoid tumor and the malignant carcinoid syndrome
4. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte a‐interferon
5. The role of interferons in the management of carcinoid tumors
6. The management of patients with advanced carcinoid tumors and islet cell carcinomas
7. Somatostatin analogue phase I trials in neuroendocrine neoplasms
8. Use of somatostatin analog in management of carcinoid syndrome
9. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome
10. Progress and hope in the treatment of gastrointestinal cancer
11. Chronic treatment with a long‐acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurrence of cholelithiasis
12. Long term results of therapy with an analogue of somatostatin (SMS 201–995) for carcinoid tumors and the malignant carcinoid syndrome
13. Resistance of metastatic pancreatic endocrine tumours after long‐term treatment with the somatostatin analogue octreotide (SMS 201–995)
14. The use of Sandostatin in insulinomas. The relation between in vivo responses, the presence of somatostatin receptors and the development of tachyphylaxis
15. Clinical review 23: The use of the long‐acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors
16. Octreotide‐associated biliary tract dysfunction and gallstone formation
17. Interferons in the management of neuroendocrine tumors and their possible mechanism of action
18. Combined alpha‐ and gamma‐interferon therapy for malignant midgut carcinoid tumors: a phase I‐II trial
19. Metastatic carcinoid tumors and the malignant carcinoid syndrome
20. Chemotherapy and biotherapy in neuroendocrine tumors
21. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet‐cell carcinoma
22. The carcinoid syndrome
23. Recombinant alpha‐2b interferon in patients with malignant carcinoid tumour
24. Treatment of carcinoid syndrome with recombinant interferon alpha‐2a
25. Long‐term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha‐interferon
26. Sandostatin in digestive endocrine tumors
27. The use of a long‐acting somatostatin analogue in the treatment of advanced endocrine malignancies with gastrointestinal symptoms
28. Analogue de la somatostatin a action prolongee et syndrome cardinoidien
29. Symptomatic treatment of malignant carcinoid syndrome with octreotide: a case report
30. La sandostatine dans les tumeurs carcinoides, les vipomes et les glucagonomes
31. Treatment of malignant carcinoid syndrome with a long‐acting somatostatin analogue
32. Carcinoides et vipomes: etude multicentrique Europe‐Etats‐Unis de la sandostatine
33. Neuroendocrine tumours of the gut: long‐term therapy with the somatostatin analogue SMS 201–995
34. Long‐term somatostatin analogue is effective treatment in patients with APUDoma‐related syndromes
35. Calcitonin and somatostatin effect in carcinoid syndrome
36. Therapy for symptoms in the carcinoid syndrome
37. Treatment of the carcinoid syndromes with somatostatin, salmon calcitonin, or octreotide
38. Treatment of gastrointestinal endocrine tumours with interferon‐alpha and octreotide
39. Carcinoid‐syndrom mit mehr als 10 jaehrigem verlauf
40. Sandostatin and gastroenteropancreatic endocrine tumors‐therapeutic characteristics
41. Somatostatin (SMS 201–995) therapy for gastrointestinal apudomas
42. Somatostatin analog (Sandostatin) treatment and in vivo somatostatin receptor imaging (SMS‐scan) in patients with carcinoid‐(like) tumors
43. Evaluation of SMS 201–995 in gastrointestinal APUDomas
44. Treatment of malignant neuroendocrine syndromes with a Iong‐acting somatostatin analogue (SMS 201–995)
45. Long‐term control of endocrine syndromes by small, infrequent doses of SMS 201–995
46. SMS 201–99 5 and endocrine tumours
47. Treatment of the malignant carcinoid syndrome (MCS) with a long acting somatostatin analogue (SMS 201–995): preliminary evidence that more is not better
48. Respuesta favorable al andlogo de la somatostatina SMS 201–995 en un paciente con sindrome carcinoide
49. Therapy of the malignant carcinoid syndrome and metastatic islet cell carcinoma
50. Carcinoid szindróama kezeléase somatostatin analoggal
51. Long acting somatostatin in carcinoid syndrome
52. Malignes‐carcinoid‐syndrom: dosis‐abhaengigkeit von 5‐HIAA ausschedidung auf octreotid (SMS 201–995)
53. Effects of Sandostatin on plasma chromogranin‐A levels in neuroendocrine tumors
54. Short‐term effects of the long‐acting somatostatin analogue SMS 201–995 in five cases of APUDoma (four with metastases) and in one case of systemic mastocytosis
55. Treatment of carcinoid syndrome with somatostatin analogue (SMS 201–995, Sandostatin). Does the benefit justify the cost
56. Effect of a somatostatin analogue (SMS 201–995) on gastrointestinal tumors
57. Somatostatin analogue SMS 201–995 in the treatment of metastatic carcinoid and islet cell tumours
58. Treatment of G‐I/pancreatic hormone hypersecretion syndromes with the long‐acting somatostatin analogue SMS 201–995
59. Treatment of malignant midgut carcinoid tumours with a long‐acting somatostatin analogue octreotide
60. Tratamiento con octreotide (SMS 201–995) en un caso de tumor carcinoide intestinal
61. Medical treatment of neuroendocrine gut and pancreatic tumors
62. Analogos de la somatostatina y tumores carcinoides
63. Short‐term administration of the somatostatin analogue SMS 201–995 in patients with carcinoid tumours
64. Occult retroperitoneal carcinoid tumor with flushing and solitary lung metastatis
65. Sandostatin in the treatment of advanced malignancies
66. Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide
67. Effects of a somatostatin analogue on symptoms and amine secretion in carcinoid syndrome
68. Therapie des metastasierten karzinoids mit dem somatostatin‐analogon octreotid and mit rekombinantem interferon alpha 2b
69. Treatment of patients with malignant carcinoid syndrome with a new somatostatin analogue, Sandostatin
70. Octreotide for carcinoid syndrome
71. Migratory thrombophlebitis during sandostatin (SMS 201–995), (Sandoz) therapy for malignant carcinoid syndrome
72. The effect of calcitonin versus a long acting somatostatin analogue (SMS 201–995) on urinary 5‐HIAA excretion in malignant carcinoid
73. Tratmiento del sindrome carcinoide con octreotide (SMS 201–995) (Treatment of the carcinoid syndrome with octreotide)
74. Treatment of APUDomas with the long‐acting somatostatin analogue SMS 201–995. Investigations of therapeutic and digestive side effects
75. Collaborative clinical trial of somatostatin analogue (SMS 201–995) in gut hormone producing tumors
76. Treatment of neuroendocrine tumors with a somatostatin analogue (Sandostatin)
77. Disseminated carcinoid in a patient with multiple endocrine neoplasia (type 1): symptomatic improvement with somatostatin analogue (SMS 201/995)
78. Hormone secretion and growth of endocrine gastrointestinal tumors during treatment with a somatostatin analogue
79. Long‐term treatment with a long‐acting somatostatin analogue (SMS 201–995) in patients with malignant carcinoid syndrome
80. Successful treatment with a long‐acting somatostatin analogue (SMS 201–995) in a patient with malignant carcinoid syndrome
81. Successful symptomatic treatment of malginant carcinoid syndrome with the somatostatin analogue SMS 201–995
82. Tratamiento farmacologico de los apudomas gastroenteropancraticos con el analogo de la somatostatina SMS 201–995 (octreotide)
83. Efficacy of octreotide + 5 fluorouracile therapy in one patient with carcinoid syndrome